Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1986 Feb;77(2):545–550. doi: 10.1172/JCI112335

Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.

E Reed, S H Yuspa, L A Zwelling, R F Ozols, M C Poirier
PMCID: PMC423377  PMID: 3944268

Abstract

The antitumor activity of cis-diamminedichloroplatinum II (cisplatin) is believed to be related to its covalent interaction with DNA where a major DNA binding product is an intrastrand N7-bidentate adduct on adjacent deoxyguanosines. A novel immunoassay was used to quantitate this adduct in buffy coat DNA from testicular and ovarian cancer patients undergoing cisplatin therapy. 44 out of 120 samples taken from 45 cisplatin patients had detectable cisplatin-DNA adducts. No adducts were detected in 18 samples of DNA taken from normal controls, patients on other chemotherapy, or patients before treatment. The quantity of measurable adducts increased as a function of cumulative dose of cisplatin. This was observed both during repeated daily infusion of the drug and over long-term, repeated 21-28 d cycles of administration. These results suggested that adduct removal is slow even though the tissue has a relatively rapid turnover. Patients receiving cisplatin for the first time on 56-d cycles, and those given high doses of cisplatin as a "salvage" regimen, did not accumulate adducts as rapidly as patients on first time chemotherapy on 21- or 28-d cycles. Disease response data, evaluated for 33 cisplatin-treated patients, showed a positive correlation between the formation of DNA adducts and response to drug therapy. However, more data will be required to confirm this relationship. These data show that specific immunological probes can readily be applied to quantitate DNA adducts in patients undergoing cancer chemotherapy.

Full text

PDF
545

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bradley M. O., Patterson S., Zwelling L. A. Thiourea prevents cytotoxicity and mutagenicity, but not sister-chromated exchanges in V79 cells treated with cis-diaminedichloroplatinum (II). Mutat Res. 1982 Sep;96(1):67–74. doi: 10.1016/0027-5107(82)90017-3. [DOI] [PubMed] [Google Scholar]
  2. Casper E. S., Kelsen D. P., Alcock N. W., Young C. W. Platinum concentrations in bile and plasma following rapid and 6-hour infusions of cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2023–2025. [PubMed] [Google Scholar]
  3. Dresch C., Najean Y., Bauchet J. Kinetic studies of 51Cr and DF32P labelled granulocytes. Br J Haematol. 1975 Jan;29(1):67–80. doi: 10.1111/j.1365-2141.1975.tb01800.x. [DOI] [PubMed] [Google Scholar]
  4. Ehrlich C. E., Einhorn L., Williams S. D., Morgan J. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report. Cancer Treat Rep. 1979 Feb;63(2):281–288. [PubMed] [Google Scholar]
  5. Einhorn L. H., Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977 Sep;87(3):293–298. doi: 10.7326/0003-4819-87-3-293. [DOI] [PubMed] [Google Scholar]
  6. Gralla R. J., Casper E. S., Kelsen D. P., Braun D. W., Jr, Dukeman M. E., Martini N., Young C. W., Golbey R. B. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med. 1981 Oct;95(4):414–420. doi: 10.7326/0003-4819-95-4-414. [DOI] [PubMed] [Google Scholar]
  7. Gullo J. J., Litterst C. L., Maguire P. J., Sikic B. I., Hoth D. F., Woolley P. V. Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion. Cancer Chemother Pharmacol. 1980;5(1):21–26. doi: 10.1007/BF00578558. [DOI] [PubMed] [Google Scholar]
  8. Howell S. B., Pfeifle C. L., Wung W. E., Olshen R. A., Lucas W. E., Yon J. L., Green M. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982 Dec;97(6):845–851. doi: 10.7326/0003-4819-97-6-845. [DOI] [PubMed] [Google Scholar]
  9. Johnson D. C., Luedke D. W., Sapiente R. A., Naidu R. G. Acute lymphocytic leukemia developing in a male with germ cell carcinoma: a case report. Med Pediatr Oncol. 1980;8(4):361–365. doi: 10.1002/mpo.2950080407. [DOI] [PubMed] [Google Scholar]
  10. Loehrer P. J., Einhorn L. H. Drugs five years later. Cisplatin. Ann Intern Med. 1984 May;100(5):704–713. doi: 10.7326/0003-4819-100-5-704. [DOI] [PubMed] [Google Scholar]
  11. Mead G. M., Green J. A., Macbeth F. R., Williams C. J., Whitehouse J. M., Buchanan R. Second malignancy after cisplatin, vinblastine, and bleomycin (PVB) chemotherapy: a case report. Cancer Treat Rep. 1983 Apr;67(4):410–410. [PubMed] [Google Scholar]
  12. Ozols R. F., Corden B. J., Jacob J., Wesley M. N., Ostchega Y., Young R. C. High-dose cisplatin in hypertonic saline. Ann Intern Med. 1984 Jan;100(1):19–24. doi: 10.7326/0003-4819-100-1-19. [DOI] [PubMed] [Google Scholar]
  13. Plooy A. C., van Dijk M., Lohman P. H. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res. 1984 May;44(5):2043–2051. [PubMed] [Google Scholar]
  14. Poirier M. C., Lippard S. J., Zwelling L. A., Ushay H. M., Kerrigan D., Thill C. C., Santella R. M., Grunberger D., Yuspa S. H. Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro. Proc Natl Acad Sci U S A. 1982 Nov;79(21):6443–6447. doi: 10.1073/pnas.79.21.6443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pritchard J. D., Mavligit G. M., Benjamin R. S., Patt Y. Z., Calvo D. B., Hall S. W., Bodey G. P., Wallace S. Regression of regionally confined melanoma with intra-arterial cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1979 Apr;63(4):555–558. [PubMed] [Google Scholar]
  16. Randolph V. L., Vallejo A., Spiro R. H., Shah J., Strong E. W., Huvos A. G., Wittes R. E. Combination therapy of advanced head and neck cancer: induction of remissions with diamminedichloroplatinum (II), bleomycin and radiation therapy. Cancer. 1978 Feb;41(2):460–467. doi: 10.1002/1097-0142(197802)41:2<460::aid-cncr2820410213>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  17. Seski J. C., Edwards C. L., Herson J., Rutledge F. N. Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol. 1982 Feb;59(2):225–228. [PubMed] [Google Scholar]
  18. Young R. C., Von Hoff D. D., Gormley P., Makuch R., Cassidy J., Howser D., Bull J. M. cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1539–1544. [PubMed] [Google Scholar]
  19. Zwelling L. A., Anderson T., Kohn K. W. DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res. 1979 Feb;39(2 Pt 1):365–369. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES